Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
BOSTON, MA – April 8, 2025 – Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
PRIME Nexus is a reusable electro-mechanical autoinjector, leveraging Portal’s PRIME needle-free platform. Compatible with 1.0 mL and 2.25 mL pre-filled syringes, Nexus offers a sustainable solution for a wide range of injectable medications and is currently available for feasibility studies.
Attendees are invited to meet with CCO Steven Kaufman for personalized demonstrations and to discuss the device's capabilities. “We’re thrilled to present PRIME Nexus alongside Gerresheimer at the PFS conference,” stated Kaufman. “The surge in injectable therapies, exemplified by GLP-1 drugs, necessitates a shift towards reusable solutions to mitigate the significant waste generated by single-use devices. PRIME Nexus represents a forward-thinking approach to injector technology.”
For companies traveling to Boston, the Portal team extends an invitation to visit their Cambridge office for a closer look at their technology.
Steven Kaufman talks with ONdrugDelivery about the world of autoinjectors, looking at the current status quo in the industry, using Portal Instruments’ PRIME Nexus™ smart reusable electromechanical autoinjector as a lens to bring into focus how things have changed and where they might be going.
July 2021 - The world we live in and the technology we use are rapidly evolving. But, when it comes to drug delivery methods, the 160-year old technology behind the needle and syringe has yet to catch wind of any radical transformation.
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
Please fill out the details below and we will get back to you shortly.